Nektar Therapeutics announced on Monday that extended use of its experimental drug, rezpeg, has demonstrated significant efficacy in promoting hair growth among individuals suffering from severe alopecia areata, an autoimmune disorder that targets hair follicles.
In a year-long study, 27% of participants receiving either a low or high dose of rezpeg achieved a clinically meaningful hair growth response, measured by the SALT Score 20, which indicates 80% or more of the scalp is covered by hair. This outcome positions rezpeg as a competitive option in the market for alopecia treatments.
Notably, the results from rezpeg are comparable to or exceed those observed with a low dose of Eli Lilly’s Olumiant, the latter of which is currently approved for severe alopecia areata but faces limitations due to safety concerns. While direct comparisons between the two drugs have yet to be conducted, the promising data from Nektar could influence treatment decisions and market dynamics in the alopecia space.
Start your 7-day trial and see what the database can do →
